



24th April 2015

**Medicines containing valproate: risk of abnormal pregnancy outcomes
(Epilim oral range, Epilim Chrono and Epilim IV range)**

Dear Pharmacist,

Further to the Direct Healthcare Professional Communication letter in December 2014, informing you of important new information and strengthened warnings related to safety of medicines containing valproate (sodium valproate, valproic acid, valproate semisodium and valpromide), please note that all required educational materials have been made available to prescribers.

The educational materials consist of a Valproate Guide for Prescribers, a Valproate Patient Information Booklet and a Valproate Patient Information Form and patients can avail of this information from their prescribing Healthcare professional.

The purpose of this letter is to ensure you are informed of the current status so that you can advise your patients (of child-bearing age) accordingly to contact their prescriber for further information about these materials.

Company contact point

Copies of the educational materials are available on www.sanofi.ie or by contacting our medical information department at IEMedinfo@sanofi.com or at telephone number (01) 4035600.

A handwritten signature in cursive script, appearing to read "Liz Bergin", is written over a horizontal line.

Dr. Liz Bergin, 022591

Medical Director, Sanofi Ireland